Get notified when TELO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Going Concern (removed) — Baseline disclosed substantial doubt about ability to continue as going concern with runway to mid-Q2 2025; current filing projects runway through Q1 2027 with no going-concern language — financial position materially improved.
TELO extends runway to Q1 2027, announces TELI merger consolidating global IP rights
Filed March 17, 2026 · Period ending December 31, 2025 · Compared to 10-K Feb 4, 2025 · ~2 min read
Key Changes
-
high
Net loss improved 37% to $10.4M from $16.5M; cash increased 5.6x to $7.3M; runway extended from mid-Q2 2025 to Q1 2027; going-concern language removed after $9.7M in new financing (ATM and Bayshore Trust equity).
MD&A: Financial Position verify on EDGAR → -
high
Merger with TELI Pharmaceuticals announced to consolidate worldwide Telomir-1 IP under single public company; TELI shareholders receive 1:1 stock exchange, resulting in ~50/50 ownership split post-merger; closing requires shareholder approval and TELI holding $1M cash.
Business: TELI Merger view on EDGAR → -
high
IND submission timeline pushed from Q4 2025 to "2026" with explicit caveats about regulatory, technical, manufacturing, and financing delays; clinical indication still being finalized and will be disclosed with IND submission.
Business: IND Timeline view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade TELO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 21, 2026 · How we verify